MA5-15705

antibody from Invitrogen Antibodies

Targeting: EIF2AK3 PEK, PERK

Western blot (Data presented on provider website)

ELISA (Recommended by provider)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

MA5-15705

Provider

Invitrogen Antibodies

Product name

PERK Monoclonal Antibody (5G5)

Antibody type

Monoclonal

Antigen

Purifed from natural sources

Description

MA5-15705 targets EIF2AK3 in indirect ELISA, WB applications and shows reactivity with Human samples. The MA5-15705 immunogen is purified recombinant fragment of human EIF2AK3 expressed in E. Coli. MA5-15705 detects EIF2AK3 which has a predicted molecular weight of approximately 125kDa.

Reactivity

Human

Host

Mouse

Isotype

IgG

Antibody clone number

5G5

Vial size

100 μL

Concentration

Conc. Not Determined

Storage

Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.

References

Submitted references

Pulsed focused ultrasound enhances the therapeutic effect of mesenchymal stromal cell-derived extracellular vesicles in acute kidney injury.

Ullah M, Liu DD, Rai S, Razavi M, Concepcion W, Thakor AS
Stem cell research & therapy 2020 Sep 14;11(1):398

---

Combined effects of Lenvatinib and iodine-131 on cell apoptosis in nasopharyngeal carcinoma through inducing endoplasmic reticulum stress.

Wang G, Zhuang J, Ni J, Ye Y, He S, Xia W
Experimental and therapeutic medicine 2018 Oct;16(4):3325-3332

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Fig. 6 Signaling pathway analysis. a Western blot and protein quantification showing the expression of p-ERK, ERK, p-MEK, MEK, and beta-actin in kidney tissue. b Western blot and protein quantification showing the expression of p-Akt, Akt, and beta-actin in kidney tissue. c Western blot and protein quantification showing the expression of SIRT3, eNOS, and beta-actin in kidney tissue. Each group has n = 3 mice. Significant difference a p < 0.05: relative to untreated control; b p < 0.05: relative to AKI; c p < 0.05: relative to AKI-EV; d p < 0.05: relative to AKI-EV-pFUS

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Figure 3. Combination of LEB and I-131 regulates apoptosis of nasopharyngeal carcinoma cells through ER stress. (A) ATF6, IER1, RERK and CHOP expression levels in HK-1 cells following treatment with LEB or/and I-131 determined by western blotting. (B) Analysis of mRNA expression levels of ATF6, IER1, RERK and CHOP expression levels in HK-1 cells. (C) Effects of LEB or/and I-131 on ER in HK-1 cells (magnification, x100). (D) GRP78 expression in HK-1 cells following combined treatment of LEB and I-131 determined by immunofluorescence (magnification, x20). (E) Adhered morphology of HK-1 cells following treatment with LEB or/and I-131 (magnification, x20). (F) JNK and P38 expression levels in HK-1 following treatment with LEB or/and I-131. The data are presented as the mean + standard error of the mean of three independent experiments. **P